Open Access
Ann Toxicol Anal
Volume 22, Number 1, 2010
Page(s) 41 - 43
Published online 12 February 2010
  1. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993; 8(1): 23–33. [PubMed]
  2. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000; 40: 161–167. [CrossRef] [PubMed]
  3. VIDAL Expert (logiciel de consultation des bases VIDAL) ver.1.3.0-10250. VIDAL & Havas Medimedia, 2009.
  4. Baselt RC. Disposition of toxic drugs and chemicals in Man, 8th edn. Foster City: Biomedical Publications, 2008.
  5. Anderson D, Reed S, Lintemoot J, Kegler S, DeQuintana S, Sandlberg M, Muto J. A first look at duloxetine (Cymbalata®) in a postmortem laboratory. J Anal Toxicol. 2006; 30: 576–580. [PubMed]
  6. Waldschmitt C, Vogel F, Maurer C, Hiemke C. Measurement of duloxetine in blood using high performance liquid chromatography with spectrophotometric detection and column switch. Ther Drug Monit. 2007; 29(6): 767–772. [CrossRef] [PubMed]
  7. Lobo ED, Quinla T, O’Brien L, Knadler MP, Heatman M. Population pharmacokinetics of orally administered duloxetine in patients : implications for dosing recommandation. Clin Pharmacokinet. 2009; 48(3): 189–197. [CrossRef] [PubMed]
  8. Document consulté sur le site le 01 juillet 2009.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.